Does “out of stock” explain a compounded copy?

The national list is the relevant record

The FDA, or Food and Drug Administration, keeps a national medicine-shortage list. Compounding: preparing medicine for a particular need.

FDA distinguishes a national shortage listing from local stock gaps, which can remain even after a shortage is resolved.

Shortage listings can create exceptions to the usual limits on compounding copies of approved drugs.

The shortage route has changed

FDA’s national shortage list did not include semaglutide or tirzepatide as of September 26, 2026.

Semaglutide is also named Ozempic or Wegovy; tirzepatide is also named Mounjaro or Zepbound. Ask for the exact product and how it is taken.

A pharmacy’s local stock problem does not by itself create the national shortage exception.

The status is dated because supply can change. Ask the person writing the prescription which rule allows the proposed medicine.

An added vitamin does not settle the question

FDA says a semaglutide preparation with added vitamin B12 may still be essentially a copy of an approved medicine.

“Essentially a copy” means close enough to the finished product that copying limits apply.

Your prescription writer must judge that this change makes a significant difference in your particular case, rather than for patients generally.

They must write down that decision and identify you as the patient who needs the change.